Topical cidofovir for plantar warts

Authors


  • Section “Study”
  • (1) Declare that the work is original and is not being assessed by any other journal.
  • (2) This work seems relevant because plantar warts have a high incidence and the importance of an appropriate treatment to improve life quality.
  • (3) Declare having taken into account the instructions for authors and ethical responsibilities, and among them, that all the authors qualify for authorship and all have declared the existence of conflict of interest both in the “website title” as in the Additional Information section of the EES.
  • (4) We declare that our work has not been previously published in another journal.

Abstract

Plantar warts are a common reason for dermatological consultations and their treatment can occasionally be a challenge. Plantar warts are benign lesions produced by the human papillomavirus (HPV) that often fail to respond to habitual treatment. Cidofovir is a potent antiviral drug that acts competitively, inhibiting viral DNA polymerase. Our aim was to assess the efficacy and safety of cidofovir cream for the treatment of viral plantar warts. We undertook a retrospective observational study of patients with plantar warts who received treatment with topical cidofovir between July 2008 and July 2011 at the Dermatology Service of the Hospital Costa del Sol, Marbella, Spain. Data about the rate of treatment response, the adverse effects, and recurrences, as well as the characteristics of the patient cohort, were recorded. We identified 35 patients who had received some previous treatment. The usual concentration was 3% (in 33 of 35 cases), applied twice a day (in 31 of 35 cases). A greater or lesser response was noted in 28 cases. There were two recurrences. Topical cidofovir seems to be a useful alternative for the therapeutic management of recalcitrant plantar common warts that fail to respond to usual treatment.

Ancillary